Silas Inman

Despite high specificity, the tests show low sensitivity for early-stage cancers, necessitating further validation through large-scale, randomized controlled trials.

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of treatment high.

Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when considering the financial impact of the popular class of drugs.

Survival rates have improved as treatment advances have multiplied, including CAR-T and bispecific antibodies.

A panel of speakers demonstrated different ways technology and artificial intelligence (AI) could greatly expand access to glaucoma care.

ChatGPT bested Google in a blinded comparison of their answers to common oculoplastic questions.

Changes have been proposed to the quality payment program that could have ups and downs, but not, perhaps for some, until 2029.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina thickness.

Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more youthful appearance, says AAO presenter.

In the threat versus opportunity session, Cecilia and Aaron Lee of the University of Washington staked out opposing positions.

Presenters at a myth breakers session at the American Academy of Ophthalmology took aim at some prevailing notions.